Showing 3061-3070 of 5621 results for "".
- Study: 1 in 10 Americans Have Not Had An Eye Exam In Five Years Or Morehttps://modernod.com/news/study-1-in-10-americans-have-not-had-an-eye-exam-in-five-years-or-more/2480339/Most people are aware they need to look after their physical health, we’re often told to eat healthier and exercise more. But many of us neglect one key part of our body’s wellbeing: our eye health. With the pandemic affecting our lives, booking an eye exam or looking
- AsclepiX Appoints Amir Shojaei, PhD, as Chief Scientific Officer and Executive Vice President, Clinical Developmenthttps://modernod.com/news/asclepix-appoints-dr-amir-shojaei-as-chief-scientific-officer-and-executive-vice-president-clinical-development/2480336/
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- IrisVision Unveils Streamlined, Lightweight New Design for Award-Winning Low Vision Headsethttps://modernod.com/news/irisvision-unveils-streamlined-lightweight-new-design-for-award-winning-low-vision-headset/2480294/
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- CNET: Mojo Vision Crams its Contact Lens with AR Display, Processor and Wireless Techhttps://modernod.com/news/cnet-mojo-vision-crams-its-contact-lens-with-ar-display-processor-and-wireless-tech/2479469/On Tuesday, startup Mojo Vision detailed its progress on a tiny AR display it embeds in contact lenses, providing a digital layer of information superimposed on what you see in the real world, according to a CNET
- Sight Sciences Announces Publication of 2-Year Outcomes of Standalone Use of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-announces-publication-of-two-year-outcomes-of-standalone-use-of-the-omni-surgical-system-in-mild-to-moderate-open-angle-glaucoma/2479466/Sight Sciences announced publication in
- United Nations Resolution Designed to Tackle Preventable Sight Losshttps://modernod.com/news/united-nations-resolution-designed-to-tackle-preventable-sight-loss/2479406/The United Nations General Assembly (UNGA) has adopted